Thrombogenesis triggered by platelet activation plays a vital role in the pathogenesis of atherosclerosis associated cardiovascular and cerebrovascular events. Currently, antiplatelet agents targeting platelet activation, including aspirin, clopidogrel and ticagrelor, are commonly used in clinical practice. However, acute coronary syndrome and stroke induced by thrombosis are still the leading causes of mortality and morbidity. Recent studies showed that platelet-endothelial cells adhesion, monocyte-endothelial cells adhesion and disorder of gut microbiota also play important roles in thrombogenesis and are potential therapeutic approaches for preventing thrombotic events. Thus, this research topic wants to collect evidence regarding the relationship between platelet-endothelial cells interaction, monocyte-endothelial cells interaction, gut microbiota and thrombogenesis in cardio-cerebrovascular disease. Additionally, this research topic also is interested in studies on potential clinical therapeutic strategies to prevent thrombogenesis.
This research topic aims to explore the underlying mechanism of thrombogenesis from the perspective of platelet-endothelial cells adhesion, monocyte-endothelial cells adhesion and disorder of gut microbiota, and to study the clinical effects and possible mechanisms of clinical drugs on preventing thrombotic events of cardio-cerebrovascular diseases.
We welcome submissions on the following topics, but are not limited to:
- The role of platelet-endothelial cells adhesion, monocyte-endothelial cells adhesion and disorder of gut microbiota in thrombogenesis
- Clinical drugs for preventing thrombotic events in clinical practice
- Mechanism of potential agent with clear chemical construction in treating thrombogenesis
- Novel risk factors of thrombogenesis based on clinical database
Thrombogenesis triggered by platelet activation plays a vital role in the pathogenesis of atherosclerosis associated cardiovascular and cerebrovascular events. Currently, antiplatelet agents targeting platelet activation, including aspirin, clopidogrel and ticagrelor, are commonly used in clinical practice. However, acute coronary syndrome and stroke induced by thrombosis are still the leading causes of mortality and morbidity. Recent studies showed that platelet-endothelial cells adhesion, monocyte-endothelial cells adhesion and disorder of gut microbiota also play important roles in thrombogenesis and are potential therapeutic approaches for preventing thrombotic events. Thus, this research topic wants to collect evidence regarding the relationship between platelet-endothelial cells interaction, monocyte-endothelial cells interaction, gut microbiota and thrombogenesis in cardio-cerebrovascular disease. Additionally, this research topic also is interested in studies on potential clinical therapeutic strategies to prevent thrombogenesis.
This research topic aims to explore the underlying mechanism of thrombogenesis from the perspective of platelet-endothelial cells adhesion, monocyte-endothelial cells adhesion and disorder of gut microbiota, and to study the clinical effects and possible mechanisms of clinical drugs on preventing thrombotic events of cardio-cerebrovascular diseases.
We welcome submissions on the following topics, but are not limited to:
- The role of platelet-endothelial cells adhesion, monocyte-endothelial cells adhesion and disorder of gut microbiota in thrombogenesis
- Clinical drugs for preventing thrombotic events in clinical practice
- Mechanism of potential agent with clear chemical construction in treating thrombogenesis
- Novel risk factors of thrombogenesis based on clinical database